ABBV vs SLB: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Slb N.V. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Slb N.V. · Energy
$52.08
+8.6% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
SLB has more upside to fair value
(+8.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
SLB |
| Current Price |
$261.70 |
$52.08 |
| Fair Value Estimate |
$259.04 |
$56.56 |
| Upside to Fair Value |
-1.0%
|
+8.6%
|
| Market Cap |
$462.4B |
$77.3B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
12.2x
|
| Price / Sales |
7.2x
|
2.1x
|
| Price / FCF |
23.6x
|
17.1x
|
| Revenue Growth YoY |
+10.2%
|
+5.0%
|
| Gross Margin |
71.5%
|
16.5%
|
| Operating Margin |
29.3%
|
13.4%
|
| Return on Equity |
-136.5%
|
11.8%
|
| Dividend Yield |
2.61% |
2.25% |
| FCF Yield |
4.25%
|
5.83%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
SLB N.V. is the world's largest oilfield services provider, operating four divisions (Digital & Integration, Reservoir Performance, Well Construction, and Production Systems) that span field development, drilling, subsea production, and carbon management for the global energy industry. The business carries a medium-quality profile: it benefits from deep technical expertise, a broad international …
Accumulation Zones
| Metric |
ABBV |
SLB |
| Zone Low |
$194.28 |
$42.42 |
| Zone High |
$220.18 |
$48.08 |
| In Buy Zone? |
No
|
No
|